Blocking Netrin-1 Slows Cancer Progression

Abstract Preclinical and early clinical data demonstrate that treating endometrial cancer with the netrin-1 inhibitor NP137 helps arrest the epithelial-to-mesenchymal transition and disease progression. Additional research is needed to understand the mechanism of action between the monoclonal antibody and chemotherapy, as well as determine whether this treatment could help patients with other cancers.